The potential of gene therapy in the peritoneal cavity

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Hoff, Catherine M ^a   Shockley, Ty R ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Cancer gene therapy; Gene therapy; Intraperitoneal gene transfer; Mesothelial cell; Peritoneum

Indexed keywords

ENZYME; GROWTH FACTOR; PROTEIN;

ANIMAL MODEL; BLADDER CANCER; CARCINOMA; CONFERENCE PAPER; DIALYSIS MEMBRANE; DNA MODIFICATION; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; MEMBRANE DAMAGE; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PERITONEAL CAVITY; PERITONEUM; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL;

EID: 0033385732     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s33     Document Type: Conference Paper

References (47)

1. Human gene marker/therapy clinical protocols [Complete updated listings]. Hum Gene Ther. 1998; 9:935-76.
2. Roush W. Antisense aims for a renaissance. Science. 1997; 276:1192-3.
3. Burke JM. Clearing the way for ribozymes. Nat Biotechnol. 1997; 15:414-15.
4. Smith AE. Viral vectors in gene therapy. Annu Rev Microbiol. 1995; 49:807-38.
5. Verma IM, Somia N. Gene therapy - Promises, problems and prospects. Nature. 1997; 389:239-42.
6. Ledley FD. Nonviral gene therapy: The promise of genes as pharmaceutical products. Hum Gene Ther. 1995; 6:1129-44.
7. Schofield JP, Caskey CT. Non-viral approaches to gene therapy. Br Med Bull. 1995; 51:56-71.
8. Dobbie JW. Ultrastructure and pathology of the peritoneum in peritoneal dialysis. In: Gokal R, Nolph KD, eds. The Textbook of Peritoneal Dialysis. Dordrecht: Kluwer Academic Publishers; 1994:17-44.
9. Nagy JA. Peritoneal membrane morphology and function. Kidney Int. 1996; 50(Suppl 56):S2-11.
10. Nagy JA, Jackman RW. Anatomy and physiology of the peritoneal membrane. Semin Dial. 1998; 11:49-56.
11. Topley N. The host's initial response to peritoneal infection: The pivotal role of the mesothelial cell. Perit Dial Int. 1995; 15:116-17.
12. Topley N, MacKenzie RK, Williams JD. Macrophages and mesothelial cells in bacterial peritonitis. Immunobiology. 1996; 195:563-73.
13. Holmdahl L, Falkenberg M, Ivarsson M, Risberg B. Plasminogen activators and inhibitors in peritoneal tissue. APMIS. 1997; 105:25-30.
14. Sitter T, Toet K, Fricke H, Schiffl H, Held E, Kooistra T. Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators. Am J Physiol. 1996; 271:R1256-63.
15. Whitaker D, Papadimitriou JM. Mesothelial healing: Morphological and kinetic investigations. J Pathol. 1985; 151:209-19.
16. Nagy JA, Shockley TR, Masse EM, Harvey VS, Jackman RW. Mesothelial cell-mediated gene therapy: Feasibility of an ex vivo strategy. Gene Ther. 1995; 2:393-401.
17. Jackman RW, Stapleton TD, Masse EM, Harvey VS, Meyers MS, Shockley TR, et al. Enhancement of the functional repertoire of the rat parietal peritoneal mesothelium in vivo: Directed expression of the anticoagulant and antiinflammatory molecule thrombomodulin. Hum Gene Ther. 1998; 9:1069-81.
18. Nagy JA, Shockley TR, Masse EM, Harvey VS, Hoff CM, Jackman RW. Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface. Gene Ther. 1995; 2:402-10.
19. Murphy J-E, Rheinwald JG. Intraperitoneal injection of genetically modified, human mesothelial cells for systemic gene therapy. Hum Gene Ther. 1997; 8: 1867-79.
20. Hoff CM, Cusick JL, Masse EM, Jackman RW, Nagy JA, Shockley TR. Modulation of transgene expression in mesothelial cells by activation of an inducible promoter. Nephrol Dial Transplant. 1998; 13:1420-9.
21. Hoff CM, Inman KL, Shockley TR. Genetic modification of peritoneal mesothelial cells for the secretion of IL-10 and IL-1-ra: Potential anti-inflammatory therapy for peritoneal dialysis [Abstract]. Perit Dial Int. 1998; 18:113.
22. Hoff CM, Piscopo D, DeLeo M, Inman K, Shockley TR. Genetic modification of peritoneal mesothelium by adenovirus-mediated gene transfer. In: Proceedings of the XIVth International Congress of Nephrology. Nephrology. 1997; 3(Suppl 1):S547.
23. Setoguchi Y, Jaffe HA, Chu C-S, Crystal RG. Intraperitoneal in vivo gene therapy to deliver al-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol. 1994; 10:369-77.
24. Setoguchi Y, Danel C, Crystal RG. Stimulation of erythropoiesis by in vivo gene therapy: Physiologic consequences of transfer of the human erythropoietin gene to experimental animals using an adenovirus vector. Blood. 1994; 84:2946-53.
25. Di Paolo N, Sacchi G, Vanni L, Corazzi S, Terrana B, Rossi P, et al. Autologous peritoneal mesothelial cell implant in rabbits and peritoneal dialysis patients. Nephron. 1991; 57:323-31.
26. Gotloib L, Shostack A, Bar-Sella P, Cohen R. Continuous mesothelial injury and regeneration during long term peritoneal dialysis. Perit Dial Bull. 1987; 7:148-55.
27. Hjelle JT, Miller-Hjelle MA, Dobbie JW. The biology of the mesothelium during peritoneal dialysis. Perit Dial Int. 1995; 15(7, Suppl):S13-23.
28. Schreiber MJ. Membrane viability in the long-term peritoneal dialysis patient. Perit Dial Int. 1997; 17(Suppl 3):S19-24.
29. Verger C. Peritoneal ultrastructure. In: Nolph KD, ed. Peritoneal Dialysis. Boston: Matinus Nijhoff Publishers; 1985:95-113.
30. Nagy JA, Jackman RW. Response of the peritoneal membrane to injury. Semin Dial. 1998; 11:242-8.
31. Hoff CM, Shockley TR. Genetic modification of the peritoneal membrane: Potential for improving peritoneal dialysis through gene therapy. Semin Dial. 1998; 11:218-27.
32. Paillard F. Mesothelial cells: The panacea for ex vivo gene therapy [Letter]. Hum Gene Ther. 1997; 8:1839-41.
33. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst. 1997; 89:21-39.
34. Tong X-W, Block A, Chen S-H, Contact CF, Agoulnik I, Blankenburg K, et al. In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol. 1996; 61:175-9.
35. Behbakht K, Benjamin I, Chiu H-C, Eck SL, Deerlin PGV, Rubin SC, et al. Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. Am J Obstet Gynecol. 1996; 175:1260-5.
36. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg. 1994; 57:1395-401.
37. Yang L, Hwang R, Pandit L, Gordon EM, Anderson WF, Parekh D. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann Surg. 1996; 224:405-17.
38. Aoki K, Yoshida T, Matsumoto N, Ide H, Hosokawa K, Sugimura T, et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1997; 8:1105-13.
39. Alvarez RD, Curiel DT. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Hum Gene Ther. 1997; 8:597-613.
40. Werthman PE, Drazan KE, Rosenthal JT, Khaluli R, Shaked A. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol. 1996; 155:753-6.
41. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. 1996; 12:1617-23.
42. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res. 1995; 55:3810-16.
43. Offner FA, Feichtinger H, Stadlmann S, Obrist P, Marth C, Klingler P, et al. Transforming growth factor-β synthesis by human peritoneal mesothelial cells. Am J Pathol. 1996; 148:1679-88.
44. Chegini N. The role of growth factors in peritoneal healing: Transforming growth factor β (TGF-β). Eur J Surg. 1997; 163(Suppl 577):17-23.
45. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for gene therapy. Hum Gene Ther. 1997; 8:803-15.
46. Varley AW, Geiszler SM, Gaynor RB, Munford RS. A two-component system that responds to inflammatory stimuli in vivo. Nat Biotechnol. 1997; 15:1002-6.
47. Watsuji T, Okamoto Y, Emi N, Katsuoka Y, Hagiwara M. Controlled gene expression with a reverse tetracycline-regulated retroviral vector (RTRV) system. Biochem Biophys Res Comm. 1997; 234:769-73.